An interdisciplinary panel held at Harvard University gathered experts in law, ethics, science, and drug policy to discuss the possibility of opening legal avenues for the therapeutic use of psychedelics in the United States. The event addressed whether the legalization of these compounds should advance quickly or wait for more scientific evidence and robust regulatory mechanisms.

During the discussions, researchers pointed out a tension between the growing social demand and the need for state oversight that can keep pace with this movement. Some participants emphasized that broad terms like “psychedelics” encompass very distinct substances and contexts, which can lead to inflated expectations or underestimate risks if policies are formulated without solid evidence bases.

Researchers and debaters also highlighted that much of the psychedelics remain illegal under U.S. federal law, despite advances in clinical research exploring their potential in treating mood disorders and substance use. Studies indicate progress in compounds like psilocybin, currently in advanced phases of clinical testing, but still without full approval from regulatory agencies like the FDA.

Risks, evidence, and access models

At the meeting, arguments for and against accelerating legalization were presented. One participant, a military veteran, argued that blocking access in therapeutic contexts could harm individuals with intense suffering, citing personal experiences with substances like ibogaine.

On the other hand, experts in medical ethics emphasized that any promise of therapeutic benefit must be proven with the same standards required for other medications, such as controlled trials and rigorous reviews.

Debaters also warned of the dangers of emerging markets without appropriate controls, including aggressive marketing and offers that may exploit healing expectations without sufficient data. The discussion also included the need to design access models that reduce harm, produce more evidence, and distribute benefits equitably, avoiding repetitions of inequalities observed in other areas of drug policy.

With information from Cañamo.Net.